Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2020 - 2023)

Lexaria Bioscience's Total Non-Current Liabilities history spans 4 years, with the latest figure at $142587.0 for Q2 2023.

  • Quarterly results put Total Non-Current Liabilities at $142587.0 for Q2 2023, up 677.51% from a year ago — trailing twelve months through May 2023 was $142587.0 (up 677.51% YoY), and the annual figure for FY2022 was $7401.0, down 85.19%.
  • Total Non-Current Liabilities for Q2 2023 was $142587.0 at Lexaria Bioscience, up from $7401.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $142587.0 in Q2 2023 to a low of $7401.0 in Q3 2022.
  • The 4-year median for Total Non-Current Liabilities is $49989.0 (2021), against an average of $61544.1.
  • The sharpest move saw Total Non-Current Liabilities crashed 85.19% in 2022, then soared 677.51% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $110821.0 in 2020, then crashed by 64.24% to $39629.0 in 2021, then plummeted by 81.32% to $7401.0 in 2022, then surged by 1826.59% to $142587.0 in 2023.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $142587.0, $7401.0, and $18339.0 for Q2 2023, Q3 2022, and Q2 2022 respectively.